SeekingAlpha · Nov 9, 2026
Nuvation Bio: The Market Is Counting New Starts While IBTROZI Stacks Patients
Ibtrozi revenue climbed 18% as long treatment duration boosts recurring sales.
NYSE · NUVB
Healthcare · Biotechnology
$3.99
Down-$0.07 (-1.72%)
Updated Nov 16, 2026, 11:49 AM
SID Score
4.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance · NUVB
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 13, 2026
NUVB closed at $3.99 after 20 trading sessions, down 10.94% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 13, 2026 | $4.03 | $4.115 | $3.945 | $3.99 | 3.09M |
| Nov 12, 2026 | $4.22 | $4.22 | $4.03 | $4.06 | 5.64M |
| Nov 11, 2026 | $4.27 | $4.38 | $4.22 | $4.29 | 2.95M |
| Nov 10, 2026 | $4.23 | $4.355 | $4.1101 | $4.20 | 3.48M |
| Nov 9, 2026 | $4.23 | $4.43 | $4.075 | $4.35 | 5.33M |
| Nov 6, 2026 | $4.21 | $4.329 | $3.975 | $4.16 | 5.34M |
| Nov 5, 2026 | $4.459 | $4.81 | $4.18 | $4.19 | 8.42M |
| Nov 4, 2026 | $4.70 | $4.75 | $4.52 | $4.73 | 8.41M |
| Nov 3, 2026 | $4.62 | $4.785 | $4.61 | $4.69 | 5.14M |
| Nov 2, 2026 | $4.80 | $4.85 | $4.59 | $4.59 | 3.72M |
| Oct 30, 2026 | $4.75 | $4.805 | $4.60 | $4.76 | 5.06M |
| Oct 29, 2026 | $4.65 | $4.835 | $4.64 | $4.77 | 6.5M |
| Oct 28, 2026 | $4.48 | $4.60 | $4.425 | $4.59 | 5.22M |
| Oct 27, 2026 | $4.51 | $4.59 | $4.36 | $4.55 | 5.06M |
| Oct 26, 2026 | $4.62 | $4.68 | $4.48 | $4.51 | 3.66M |
| Oct 23, 2026 | $4.62 | $4.66 | $4.44 | $4.57 | 3.19M |
| Oct 22, 2026 | $4.83 | $4.91 | $4.655 | $4.70 | 5.81M |
| Oct 21, 2026 | $4.77 | $4.96 | $4.72 | $4.85 | 4.5M |
| Oct 20, 2026 | $4.51 | $4.82 | $4.46 | $4.77 | 6.85M |
| Oct 19, 2026 | $4.48 | $4.60 | $4.345 | $4.48 | 4.22M |
The latest Smart Investors Daily articles mentioning NUVB.
Company
Market Activity
Research & News
NUVB research
Company profile and research snapshot.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 5, 2026 | RBC Capital | Outperform | — |
| Sep 30, 2026 | Citigroup | Buy | — |
| Sep 16, 2026 | Citizens | Market Outperform | — |
| Sep 16, 2026 | Wedbush | Outperform | — |
| Aug 21, 2026 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
SeekingAlpha · Nov 9, 2026
Ibtrozi revenue climbed 18% as long treatment duration boosts recurring sales.
Yahoo · Nov 8, 2026
Nuvation Bio (NYSE:NUVB) reported $45 million in third-quarter 2026 revenue as U.S. sales of lung cancer treatment IBTROZI rose 18% from the previous quarter, even as the company said new patient starts declined across the broader ROS1 treatment market. IBTROZI generated $27.5 million in net U.S. p
Benzinga · Nov 5, 2026
RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowers the price target from $20 to $17.
Yahoo · Nov 5, 2026
Management weighed a European milestone and new glioma data ahead of 2027.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning NUVB.